Background: LRP1 activation is neuroprotective in vitro. The role of LRP1 in axonal plasticity and regeneration is unknown. Results: LRP1-dependent cell signaling that includes TrkC activation promotes axonal growth in the CNS. Conclusion: LRP1 agonists promote regeneration after spinal cord injury. Significance: A significant role is established for LRP1 in axonal growth and regeneration after CNS injury, identifying a novel class of therapeutic targets for neurological disorders.
signaling receptor for diverse ligands including tissue-type plasminogen activator (tPA), matrix metalloproteinase-9 (MMP-9), and activated α 2 -macroglobulin (4) (5) (6) (7) (8) . LRP1 agonists activate cell signaling by tyrosine phosphorylation of NPXY motifs present in the LRP1 cytoplasmic domain, and by binding of signaling adaptor-proteins, such as Shc and JIP (9, 10) . In Schwann cells, LRP1 activates PI3K/Akt mediated cell survival signaling pathways and counteracts endoplasmic reticulum (ER) stress (11, 12) . LRP1 also interacts with other receptors, including integrins (13), platelet-derived growth factor (PDGF) receptors (14) and urokinase-type plasminogen activator receptor (uPAR) (15) . As a result, LRP1 functions in a diversity of cellular activities including cell signaling and metabolism, migration, and bloodbrain barrier integrity (16, 17) .
LRP1 is widely expressed in uninjured central and peripheral neurons (Allen Brain Atlas; www.brain-map.org (18, 11) . Recent reports have suggested a potential role for LRP1 in neural function and growth: 1) LRP1 acts as a prosurvival and migratory receptor in Schwann cells after peripheral nerve injury (11, 19) ; 2) LRP1 transduces a signal for phagocytosis of degraded myelin in experimental models of multiple sclerosis (20); and 3) LRP1 modulates processing of the amyloid precursor protein (20) (21) (22) 3) . Recently, LRP1 agonists were also reported to induce transactivation of TrkA in a Src family kinase (SFK)-dependent manner, promoting neurite outgrowth from PC12 cells (23). The latter findings identify a candidate mechanism for potential actions of LRP1 on axonal function, and suggest the hypothesis that LRP1 activation could promote axonal sprouting and regeneration in the adult CNS. Synthetic LRP1 ligands have been generated, including several fusion proteins that can be readily infused into the CNS to test potential activities in injury models. We now report potent effects of LRP1-binding ligands on axonal growth in vitro and after spinal cord injury in vivo, identifying a novel LRP1-dependent cell signaling mechanism involved in CNS plasticity and regeneration. These effects result from canonical LRP1 ligand transactivation of Trk.
EXPERIMENTAL PROCEDURES
Experimental design-In vitro experiments determined whether LRP1 agonists promote neurite outgrowth from cultures of dissociated primary adult dorsal root ganglion (DRG) neurons, and on signaling mechanisms activated by LRP1 receptor signaling. A second set of "ex vivo" experiments determined whether intrathecal infusion of LRP1 agonists for three days would also stimulate growth-related neuronal signaling and neurite outgrowth in DRG neurons that were subsequently removed and cultured in vitro. Finally, in vivo experiments assessed the ability of intrathecal infusions of LRP1 agonists to promote sprouting or regeneration of the central processes of DRG neurons projecting through the dorsal columns after C4 dorsal spinal cord lesions. All experiments examined the same population of large diameter, neurofilament-200 (NF200) expressing, NT-3 sensitive DRG neurons.
Reagents-Glutathione-S-transferase (GST) fusion proteins that directly bind LRP1 and are LRP1 agonists were prepared as previously described (24, 25) . Purified GST and GST-fusion proteins were subjected to chromatography on Detoxi-Gel endotoxin-removing columns (Pierce) and endotoxin-dialysis decontamination (8) . LRP1 agonists include: 1) an 18 kDa receptor binding domain of α2-macroglobulin (α 2 M), henceforth referred to as RBD (25-27); and 2) 18 kDa LRP1 binding domain of matrix metalloproteinase-9, the hemopexin domain, henceforth referred to as PEX (28, 8) . The LRP1 antagonist, receptor associated protein (RAP) and GST controls were prepared as previously described (27, 29) . The resulting protein preparations yielded clearly defined bands, with the correct molecular masses when assessed by Coomassie Blue Staining of SDS gels or immunoblot analysis with GST-specific antibody. LRP1-dependent cell signaling was confirmed by inhibition of pERK with RAP. Stability of fusion proteins over time at 37°C (for subsequent in vivo infusions) was assessed by incubating 100 nM RBD or GST in PBS at 37°C for 0, 24, 48, 72 and 96 h, and adding to PC12 cells for 10 min and examining ERK activation, as described below.
Neurite outgrowth in cultures of adult DRG neurons-In vitro studies: Primary cultures of adult F344 L4-L6 DRG neurons were cultured on poly-L-lysine (16.6 µg/ml) coated 12 well plates, as previously described (30). Cells were treated with 100 nM RBD, PEX, or GST for 18 or 24 h. In some assays, cells were pretreated with GST-RAP (200 nM), 30 min prior to the addition of LRP1 agonists. Some conditions included plating of cells on inhibitory myelin substrates, as described below. Myelin coated plates were prepared by extracting myelin from rat spinal cord, diluting in water at 10 µg per well, drying overnight at room temperature and washing with DMEM/F-12 the next day before use.
Cells were fixed and labeled for neurofilament 200 (NF200), a specific marker of neurites emerging from the NT-3-responsive subpopulation of dorsal root ganglion (DRG) neurons (31,32) The in vitro portion of our studies focused on the NT-3-responsive population of DRG neurons because they are the subject of the subsequent spinal cord injury model in vivo. Images were acquired manually at 100x magnification, and longest neurite length per cell was measured in a minimum of 80-100 neurons per well using Image J. Quantification was performed in a blinded manner. Experiments were replicated twice with internal triplicates. Immunolabeling was performed using anti-neurofilament-200 (NF200 @1:4000, Millipore). Dual labeling of NF200 and LRP1 was performed in frozen DRG sections using a polyclonal LRP1 antibody (Sigma @1:1000) (11) .
Ex-vivo studies: Adult F344 female rats weighing 150-200 g (N=28 rats) were anesthetized with a mixture (2 ml/kg) of ketamine (25 mg/ml), rompun (1.8 mg/ml) and acepromazine (0.25 mg/ml). National Institutes of Health and Institutional Animal Use and Safety Committee guidelines for laboratory animal care and safety were strictly followed for all animal use and postoperation care. Alzet osmotic mini-pumps (model 1003) were implanted in the spinal cord at the L4-5 level for intrathecal delivery of GST or RBD (5 µM; 1 µl/h) for 3 days. After infusions, DRGs were rapidly isolated, lysed in RIPA buffer for subsequent immunoblot analysis or cultured for 18 h, fixed with 4% PFA, stained for NF200, imaged and quantitated as described above.
Cell signaling studies in primary adult DRG neurons-Immunoblots: L4-L6 rat DRGs were harvested and plated on poly-L-lysine-coated 6-well plates. The cells were treated with 200 nM RBD, PEX, GST or NT-3 (positive control; Abcam; 20 nM), or vehicle (0.01% Brij35 in PBS) for 30 min in neural basal media. In some cases, cells were pretreated with the Trk activation inhibitor, k252a (10 nM), or with a SFK inhibitor, PP2 (1 µm) , 30 min prior to the addition of LRP1 agonists. Cell extracts were prepared using a total protein extraction kit (Millipore). An equivalent amount of cellular protein (20-50 µg/lane) was subjected to SDS-PAGE, immunoblotting and densitometry as described previously (11, 12) . Primary antibodies used included: pTrkC (1:1000, Syd Laboratories), tTrkC (Abcam), pERK or tERK (1:1000, Cell Signaling Technology). Experiments were replicated 5-11 times. Blots were scanned (Cannoscan) and densitometry was performed using Image J as previously described (8, 11) .
Immunofluorescence: Dissociated DRG neurons were plated on poly-L-lysine-coated coverslips, treated with 100 nM PEX, GST, NT-3 (positive control; 20 nM), or vehicle (0.01% Brij35 in PBS) for 30 min in neural basal media. In some cases, cells were pretreated with a SFK inhibitor, PP2 (1 µm), 30 min prior to the addition of LRP1 agonist. and then fixed with 4% paraformaldehyde.
Dual label immunofluorescence was performed as described (11) . Briefly, cells were incubated with primary antibodies to pTrk (1:500 Y490; Santa Cruz) or pERK (1:1000; Cell Signaling Technology) and with the appropriate fluorescent antibodies (Alexa Fluor 488-or 594-conjugated antibodies). A second primary antibody, NF200 (1:4000; Millipore), and secondary antibody were added. Preparations were mounted on slides using Prolong Gold with DAPI for nuclear labeling (Invitrogen). Images were captured on an Olympus Fluoview1000 confocal microscope and quantified using Veloctiy 3D Image Analysis Software (PerkinElmer). A total of 80 to 110 neurons were counted from 4 independent experiments Spinal cord injury and tissue processing-17 adult female Fisher 344 rats weighing 150-200 g were deeply anesthetized as described above under animal protocols approved by the Institutional Animal Welfare Committee. Alzet osmotic minipumps were implanted in the spinal cord at the L4-5 level for intrathecal delivery of either 5 µM GST (N=8 animals) or RBD (N=9 animals). Three days later, C4 dorsal column spinal cord lesions were placed using a Scouten tungsten wire knife (33) The lesion site was filled with syngeneic bone marrow stromal cells to provide a matrix in the lesion site to which injured axons could attach and grow (34). Rat marrow stromal cells were prepared as described previously (35, 36) and transplanted into the lesion site using glass pipettes and a picospritzer. Pumps were replaced at the same time with fresh RBD. Dorsal-column sensory axons were labeled transganglionically by cholera toxin B subunit (CTB) injection into the sciatic nerve (2 µl of 1% solution per sciatic nerve) 3 days before perfusion (36-38). Four weeks after spinal cord lesions, animals were transcardially perfused with 4% paraformaldehyde, post-fixed overnight, and cryoprotected in 30% sucrose at 4°C. Spinal cords were sectioned sagittally on a cryostat set to 30 µm intervals. All sections were processed free-floating. CTB-labeled sensory axons were visualized as described previously (36). GFAP was detected subsequently in the same sections by fluorescence labeling. We quantified the mean number of dorsal column sensory axons penetrating the lesion site, the total length of axons penetrating the lesion site, and the mean number of axons reaching the mid-portion of the lesion site using serial 30-µm-thick sections (a series of 1-in-7) labeled for CTB and GFAP. The number of CTB-labeled axons encountered at a virtual line drawn in the mid-portion of the graft, identified by GFAP labeling (Fig. 4A) , was counted using a 10x ocular with a calibrated grid and a 40x objective. The total length of CTB-labeled axons within the lesion site was quantified by acquiring images of entire grafts at 200x magnification, capturing the images in the Neuron plugin of Image J, and tracing every individual axon within the graft. The total length of all axons in each CTB-labeled section from every animal was summed and mean values across groups were compared. In addition, total axons in the graft that could be resolved individually were quantified; multiple axons that could not be resolved as separate axons were quantified as a single axon count. To account for potential differences between CTB axonal labeling efficiency in different animals, the total number of CTB-labeled axons in the dorsal columns approaching the lesion site (500 µm caudal to the lesion) was also quantified in each subject; the total numbers of axons in the graft and reaching the mid-portion of the graft was then divided by this value. Mean values for axon number and midline-crossing axons were averaged per subject and expressed as mean ± SEM.
Statistical analysis-Differences between multiple treatment groups were assessed using one-way ANOVA. Individual group differences were assessed using post-hoc Fisher's or NewmanKeuls Multiple Comparisons Tests. Comparison of two groups were made using two-tailed t-test with a significance criterion of P<0.05. All procedures were conducted in a blinded fashion. All animals entered into this study were reported and used in the subsequent analyses of results (39).
RESULTS
LRP1 is expressed in adult DRG neurons, and LRP1 activation increases neurite outgrowth-Double labeling for LRP1 and NF200, a marker for large diameter neurons (30), demonstrated that LRP1 is expressed by intact adult large diameter DRG neurons and some smaller DRG neurons (Fig. 1A) . We then determined whether LRP1 activation promotes growth of cultured adult DRG neurons. Dissociated DRG cultures from naïve adult rats were treated with the LRP1 agonists, RBD, PEX, the control protein, GST or were untreated. RBD and PEX significantly increased neurite outgrowth of NF200-labeled neurites greater than 2-fold compared to the GST control ( Fig. 1B, 1C ; P<0.005 comparing PEX or RBD to GST) after 18 h. To test whether LRP1 is responsible for the effects of RBD and PEX on neurite outgrowth, cells were pretreated with GST-RAP, a wellestablished LRP1 antagonist that binds to LRP1 and precludes binding of other ligands (29) or with GST as a control. When added alone, GST-RAP did not activate neurite outgrowth (P=0.9). However, GST-RAP significantly reduced the growth-promoting effects of RBD and PEX, indicating specific activity through LRP1 ( Fig. 1B,  1C ; P<0.05 comparing PEX to PEX+RAP, and P<0.05 comparing RBD to RBD+RAP). In a separate set of experiments, effects of LRP1 signaling in permissive (PLL) or inhibitory (myelin) environments were examined after 24 h. Addition of RBD significantly increased neurite outgrowth (4-fold) on PLL ( Fig. 1D ; P<0.01). Moreover, RBD significantly overcame myelinmediated inhibition, increasing neurite outgrowth by 3-fold on the myelin substrate (Fig. 1D , P<0.05). Thus, LRP1 activation significantly promotes neurite outgrowth from adult DRG sensory neurons under both permissive and nonpermissive conditions. LRP1 ligands elicit TrkC signaling in DRG neurons by transactivation of the LRP1 receptor-Previous reports indicate that LRP1-dependent cell signaling facilitates neurite outgrowth by transactivating TrkA in PC12 cells (23). To understand the cell signaling mechanisms underlying neurite outgrowth in adult DRG neurons, we tested whether LRP1 agonists activate TrkC. We focused on TrkC expressing populations of DRG neurons because their axons are lesioned by the dorsal column spinal cord injury used in our in vivo studies, whereas TrkA-and TrkBexpressing DRG neurons are not. Addition of either NT-3, serving as a positive control, or the LRP1 ligand, PEX, for 30 min to adult DRG cultures resulted in activation of TrkC compared to GST and vehicle-treated controls ( Fig. 2A, 2B ; P<0.01). Both 170 kDa and 150 kDa pTrkC bands were identified, as previously described (39). Next, we measured ERK activation after treatment with PEX; activation was increased compared to controls ( Fig. 2C ; quantified in Fig. 2D ). To test whether Trk activation was required for LRP1-dependent cell signaling, we added the Trk inhibitor, k252a, in the presence of PEX and measured ERK activation (Fig. 2C ). PEX significantly activated ERK (P<0.01), and this activation was blocked by k252a (Fig. 2D ). Taking the results of Fig. 2 together, we conclude that LRP-1-dependent cell signaling requires TrkC activation at least in part: that is, PEX activates TrkC ( Fig. 2A, B) , which canonically activates ERK; addition of k252a in the presence of PEX reduces ERK levels to near baseline. While it is possible that LRP1 ligands also activated ERK through TrkA and B receptors in these mixed DRG cultures, the nearly complete reduction of pERK by the addition of k252a indicates that all PEX-induced Trk signaling is blocked by k252a, including that portion generated by TrkC activation.
To further investigate mechanisms through which LRP1 agonists activate signaling in adult DRG neurons, we treated adult DRG neurons with the Src-family kinase (SFK) inhibitor, PP2, in the presence of PEX or RBD. Previously, PP2 has been reported to block LRP1-induced transactivation of TrkA (23). PP2 significantly inhibited both PEX-and RBD-induced ERK activation (P<0.05; Fig. 3A-C) . In contrast, PP2 did not inhibit ERK phosphorylation induced by NT3, and when added alone, PP2 did not activate cell signaling. RBD also activated Akt signaling (Fig. 3D) , and this canonical Trk-related signaling was inhibited by PP2 (Fig. 3D) . We next showed that PP2 specifically blocks LRP1-dependent cell signaling in TrkC-expressing neurons using double labeling for NF200 (expressed only by TrkC-bearing DRG neurons) (31,32) and pTrk: NT-3 treatment induced pTrk labeling and this was not affected by addition of PP2 (data not shown; PEX also induced pTrk labeling in the NF200-labeled population of DRG neurons, and this labeling was attenuated by addition of PP2 (Fig. 3E P<0.05) ). These data are further confirmed by quantification in Fig. 3F . Double labeling for NF200 and pERK revealed that PEX induced pERK in NF200-expressing adult DRG neurons, and this labeling was eliminated by addition of PP2. Collectively, these findings strongly suggest that LRP1 transactivates TrkC in an SFK-dependent manner.
Intrathecal infusions of the LRP1 ligand, RBD, promote neurite outgrowth through ERK activation: Ex vivo experiments-To determine whether intrathecal infusions of RBD effectively target and elicit signaling from neurons with central axonal projections, we chronically infused either RBD or GST (control) into the lumbar intrathecal compartment. First, we tested whether LRP1 agonists remain bioactive at body temperature over time. PC12 cells were stimulated with RBD or GST that had been incubated for 0-96 h at 37°C. RBD activated ERK, confirming bioactivity of RBD even after incubation for 96 h at 37°C (Fig. 4A) . GST alone had no effect, as anticipated. Next, osmotic mini-pumps were implanted in the back, with the tip of a delivery catheter positioned in the subdural space between L4 and L5 (Fig. 4B) . Three days after initiating intrathecal infusions of RBD or GST, L4 DRGs were isolated and lysed in RIPA buffer for immunoblot analysis. RBD-treated DRGs showed significant increases in phosphorylation of TrkC and ERK compared to GST-treated rats (Fig. 4C) . These findings were further confirmed by densitometry (Fig. 4D) . We repeated intrathecal infusions of RBD and GST for three days, and then isolated and cultured DRGs to measure neurite outgrowth after 24 h. Findings were compared to DRGs removed from naïve controls. RBD-treated DRGs extended significantly longer NF200-labeled neurites than neurons from GST or naïve animals (Fig. 5A, P<0 .001 comparing RBD to both GST and naïve groups). GST-infused controls showed a non-significant increase in neurite length compared to naïve controls, a potential consequence of intrathecal catheter placement causing a mild conditioning effect on DRG neurons. RBD markedly and consistently increased ERK phosphorylation compared to both naïve and GST-infused controls (Fig. 5B, 5C P<0.01). These findings indicate that intrathecal infusions of LRP1 agonists are an effective means of activating downstream canonical Trk receptor signaling and enhancing neurite growth.
Intrathecal infusions of RBD promote axonal sprouting and regeneration after spinal cord injury-Given the significant effects of LRP1-dependent cell signaling on regeneration-related neurite outgrowth in vitro, we next determined whether targeting of LRP1 receptors was an effective mechanism for influencing axonal growth after spinal cord injury. Rats underwent C4 dorsal column lesions, which completely transect all dorsal column sensory axons projecting to the nucleus gracilis (Fig. 6A,B) ; this is a standard model for assessing the potential of novel compounds to enhance CNS axonal plasticity and regeneration (37,41-43) The lesion site was filled with syngeneic bone marrow stromal cells, to provide a matrix in the lesion site into which injured axons can attach (34,36); without this matrix, even stimulated axons will not regenerate into the lesion. Notably, animals infused with RBD exhibited significant increases in axonal regeneration into the lesion site compared to GSTinfused animals (Figs. 6C-F) . Animals treated with RBD showed a 71% increase in the total proportion of all labeled dorsal column axons regenerating into the lesion site compared to control-infused subjects (P=0.03): the number of CTB-labeled axons in the lesion site constituted 28.7% of all CTB-labeled axons present in the dorsal column projection, compared to 16.8% in controls (Fig. 6G) , indicating recruitment of regeneration in more than one-quarter of all labeled axons. The efficiency of axonal labeling did not differ significantly between RBD-and GST-infused groups (193 ± 3.5 labeled axons per subject in RBD-treated animals versus 204 ± 4.7 in GST-treated animals, p=0.44). Moreover, the total length of all axons regenerating into the lesion site was 3.6-fold greater in RBD-treated animals compared to controls (p < 0.01, Fig. gH) . In addition, the distance over which axons regenerated also significantly increased in RBDtreated animals, reflected by the number of axons reaching the middle of the lesion site (120% increase; P<0.001), compared to controls (Fig. 6I) .
Furthermore, analysis of histological sections demonstrated numerous CTB-labeled axons sprouting into the host gray matter as axons approached the lesion site; quantification revealed a significant 80% increase in the number of these sprouting sensory axons in the host gray matter (P<0.05, Fig. 7 ). Growth of transected axons remote from the lesion site has been referred to as "regenerative sprouting" (44). Sectioning of the medulla in all animals confirmed that lesions were complete and no axons were spared, since CTB tracer was not present in the nucleus gracilis (Fig.  8) .
DISCUSSION
Findings of this study identify an entirely novel mechanism for promoting axonal sprouting and regeneration in the CNS in vivo: the targeting of LRP1 receptors. Agonists of this LDL-gene family receptor result in activation of canonical Trk signaling in a SFK-dependent manner, resulting in ERK and Akt activation. As a result, there is increased neurite outgrowth in vitro together with amelioration of myelin-mediated inhibition. Intrathecal infusions of LRP1 agonists result in significant increases in axonal sprouting and regeneration after spinal cord injury. Collectively, these findings indicate that targeting of lipoprotein receptors can activate cell signaling relevant to axonal growth in vitro and in vivo.
While the LDL family of receptors has classically been associated with modulation of lipoprotein metabolism, modern studies indicate a diversity of roles for this receptor system in various aspects of cellular activities, including cell signaling and function. However, the role of LRP1-dependent cell signaling in CNS injury in vivo has not been extensively examined to date. Mice with conditional loss of LRP1 in post-mitotic neurons exhibit alterations in brain lipid metabolism, synapse loss and neurodegeneration (45). LRP1 also modulates amyloid precursor protein (APP) processing through interaction with apolipoprotein E (ApoE) (46,3); this may account for the selective vulnerability of specific ApoE genotypes to development of Alzheimer's disease. LRP1 receptors are also present on glia; e.g., LRP1 is expressed by Schwann cells after peripheral nerve injury (11) and is thought to contribute to the ability of these cells to survive injury and contribute to peripheral nerve regeneration. Our data substantially expand the known roles of LRP1 in the nervous system by demonstrating significant effects on axonal growth and regeneration in in vivo models of central nervous system injury.
We did not study functional outcomes in this study because the ascending dorsal column sensory projection was transected several levels below its normal target of projection, the nucleus gracilis, and axons did not regenerate over the extended distance that would be required to support functional recovery. Rather, we used this model because it is of established value in determining whether candidate therapies enhance the plasticity and regeneration of CNS axons that otherwise fail to grow after spinal cord injury (34,36,41-43) Indeed, our findings reveal significant effects of LRP1 agonists on axonal growth after injury in this valuable model system. Future studies will explore outcomes in clinically relevant contusive SCI lesion models that result in motor and sensory deficits; a hypothetical advantage of LRP1 agonists in these models is the broad expression of LRP1 receptors on numerous CNS neuronal populations (18), suggesting that drugs targeting these receptors could broadly activate the intrinsic CNS neuronal growth response to injury (30,47).
Mechanisms underlying modulation of axonal growth include LRP1-initiated cell signaling and transactivation of TrkC. A previous report suggested that α2-macroglobulin may directly bind Trks independently of LRP1 (48). However, our results and others (23) indicate that structurally diverse LRP1 ligands, including MMP-9-PEX and RBD, all activate Trks, Akt and ERK1/2, and these actions are blocked by RAP; RAP precludes binding of LRP1 ligands and thus blocks LRP1-initiated cell signaling in multiple cell culture models (5, 8, 49 ). Thus, effects of LRP1 agonists in our models appear to depend on direct LRP1 binding, rather than direct binding to Trk receptors.
A major point of significance in this work lies in the observation that LRP1 activates canonical signaling associated with neurotrophin receptors; neurotrophins in turn exhibit potent effects in models of CNS injury and neurodegeneration (34,50-52) potentially provide a new means of stimulating neurotrophin receptors through the use of LRP1 agonists, which have now been shown to stimulate both TrkA-and TrkC-mediated signaling (23, and present findings). The activity of LRP1 agonists on a diversity of Trk receptors could result in therapeutic benefits extending beyond the large diameter dorsal root ganglion neuronal population targeted in this study: for example, LRP1 transactivation of TrkA (23) could alter aberrant patterns of nociceptive axon sprouting that are thought to contribute to chronic pain after SCI (53) or in other conditions. On the other hand, as with any therapy that targets axonal sprouting and regeneration, non-targeted sprouting induced by LRP1 agonists could also worsen functional outcomes. These possibilities must be addressed in future studies.
Moreover, intrathecal infusions of LRP1 agonists in this study result in enhancement of central axonal regeneration that is similar in nature to the effects of "conditioning lesions". However, conditioning lesions are clinically impractical whereas intrathecal infusions of LRP1 agonists are clinically relevant. Future studies will define the therapeutic window for infusion of LRP1 agonists in central and peripheral nerve injury, and the effects of LRP1 receptor targeting on other axonal populations, including motor axonal systems of the spinal cord. Future studies will also address whether the combination of LRP1 infusions with NT-3 chemotropic gradients beyond a spinal cord lesion will enhance the number of sensory axons regenerating that fully bridge the lesion site, a combinatorial approach taken in previous studies using conditioning lesions (34, 36-38).
We are attempting to generate small molecules and bioactive peptides that bind and initiate LRP1-dependent cell signaling to further enhance clinical relevance. For example, the GST-fusion protein used in these studies, the receptor binding domain (RBD) of α2-macroglobulin, also contains a distinct binding domain for beta amyloid (Aß): this could potentially result in the formation of RBD-Aß complexes (24) that accelerate betaamyloid-mediated neuronal degeneration (54). Yet other reports indicate that LRP1 agonists might reduce aberrant amyloid precursor protein processing (55), and LRP1-dependent cell signaling in neurons and glia appears to consistently result in pro-survival effects (56). Moreover, the LRP1 ligand derived from the hemopexin domain of MMP-9, PEX, does not bind Aß and would be unlikely to influence Alzheimer's disease-related pathology. The total length of all axons penetrating the lesion site is increased by 3.6-fold in RBD-infused subjects (*P<0.01), and (I) RBD infusion also increases the distance over which axons regenerate into the lesion site, reflected by the proportion of all labeled axons per subject that reach the lesion midline (**P<0.001 compared to GST-controls). Data are mean±SEM 
